Skip to main content

4 Result(s)

within Scott P. Myrand Remove this filter

and

  1. No Access

    Article

    Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer

    Introduction LY2603618 is a selective inhibitor of checkpoint kinase 1 (CHK1) protein kinase, a key regulator of the DNA damage checkpoint, and is predicted to enhance the effects of anti...

    Giorgio Scagliotti, ** Hyoung Kang, David Smith… in Investigational New Drugs (2016)

  2. No Access

    Article

    Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors

    Background This Phase-I-study aimed to determine the recommended Phase-II-dosing-schedule of LY2334737, an oral gemcitabine prodrug, in patients with advanced/metastatic solid tumors. Pha...

    Sandrine J. Faivre, Anthony J. Olszanski, Karin Weigang-Köhler… in Investigational New Drugs (2015)

  3. No Access

    Article

    Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study

    Purpose Gemcitabine (G) is standard therapy for pancreatic cancer. Enzastaurin (E) inhibits PKCβ and PI3K/AKT signaling pathways with a dose-dependent effect on growth of pancreatic carcinoma xenografts. Data sug...

    Donald A. Richards, Paul R. Kuefler, Carlos Becerra… in Investigational New Drugs (2011)

  4. No Access

    Protocol

    Genoty** for Functionally Important Human CYP2D6*4 (B) Mutation Using TaqMan Probes

    The microsomal enzyme cytochrome P450 2D6 (CYP2D6), also known as debrisoquine 4-hydroxylase, is involved in the oxidative metabolism of many widely used drugs, including neuroleptics, tricyclic antidepressant...

    Michael M. Shi, Scott P. Myrand, Michael R. Bleavins… in Molecular Pathology Protocols (2001)